SWOT Analysis for Beta Drugs Ltd.

Benjamin Graham Value Screen
30 Day SMA crossing over 200 Day SMA, and current price greater than open
Consistent Highest Return Stocks over Five Years
Relative Outperformance versus Industry over 1 Month
Relative Outperformance versus Industry over 1 Month
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
Top Gainers

PE higher than Industry PE
High PE (PE > 40)
Oversold by Money Flow Index (MFI)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of capital to generate profits - RoCE declining in the last 2 years
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Low Piotroski Score : Companies with weak financials
Weak Momentum: Price below Short, Medium and Long Term Averages
Companies Increasing Debt as per Annual Report
RSI indicating price weakness
Stocks Underperforming their Industry Price Change in the Quarter